Date:	<u>March</u>	<u>25th, 2022</u>
Your Name:		Yuhong Dai
Manuscript	Title: _	_Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib
for refracto	ry met	astatic colorectal cancer
Manuscript	numbe	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March :	25 th , 2022
Your Name:		<u>Li Sun</u>
Manuscript	Title: _	_Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib
for refracto	ry meta	astatic colorectal cancer
Manuscript	numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March 3	25 th , 2022	
Your Name:		Liang Zhuang	
Manuscript	Title: _	_Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib	
for refracto	for refractory metastatic colorectal cancer		
Manuscript	numbe	r (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March 2	25 th , 2022		
Your Name:		Mingsheng Zhang		
Manuscript 1	Title:	Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib		
for refractor	for refractory metastatic colorectal cancer			
Manuscript r	number	(if known):		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement:

Date:	<u>March</u>	<u>25th, 2022</u>
Your Name:		Yanmei Zou
Manuscript	Title: _	Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib
for refracto	ry met	astatic colorectal cancer
Manuscript	numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus,	None	
	manuscript writing or educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement:

Date:	March :	25 th , 2022		
Your Name:		Xianglin Yuan		
Manuscript ⁻	Title: _	_Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib		
for refracto	ry meta	astatic colorectal cancer		
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement:

Date:	<u>March</u>	25 th , 2022
Your Name:		Hong Qiu
Manuscript	Title: _	<u>Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruguintinib</u>
for refracto	ry met	astatic colorectal cancer
Manuscript	numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the initialNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	None	
	educational events		
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	None None	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non- financial interests	None	

I declare that I have no support for the present manuscript, no grants or contracts from any entity, no royalties or licenses, no consulting fees, no payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, no payment for expert testimony, no support for attending meetings and/or travel, no patents planned, issued or pending, no Participation on a Data Safety Monitoring Board or Advisory Board, no leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, no stock or stock options, no receipt of equipment, materials, drugs, medical writing, gifts or other services, either other financial or non-financial interests.

Please place an "X" next to the following statement to indicate your agreement: